Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Pharma Manufacturing and Pandemic Preparedness

    By Global Biodefense StaffApril 7, 2016
    Swine Flu H1N1 Pandemic Analysis
    Credit: Shutterstock, modified by Global Biodefense
    Share
    Facebook LinkedIn Reddit Email

    Swine Flu H1N1 Pandemic AnalysisThe Biomedical Advanced Research and Development Authority (BARDA) has identified continuous manufacturing (CM) as an emerging technology within the pharmaceutical industry that has significant potential to improve agility, flexibility, cost, and robustness in medical countermeasure manufacturing for disaster and pandemic preparedness.

    BARDA’s Innovations in CM initiative was launched in 2015, focusing on the need for a national innovation policy regarding advanced manufacturing and recommendations to develop and sustain advanced manufacturing capability and capacity domestically. BARDA’s role to champion CM as a facet of advanced manufacturing has been described in the recently released Advancing Manufacturing: A Snapshot of Priority Technology Areas Across the Federal Government (2016) by the Obama administration.

    Although the continuous input of active pharmaceutical ingredient in the manufacturing of small-molecule drug products has been met with some success, as has the production of biological products (e.g. monoclonal antibodies) by means of continuous perfusion bioreactors, “true” end-to-end continuous manufacturing from raw materials and reagents to drug product at a commercial scale has not yet been realized.

    BARDA research and development goals are currently designed to advance continuous manufacturing beyond what is feasible today and facilitate the industry-wide adoption of this emerging technology.

    Future BARDA investments will focus on the application of innovative CM technologies directly into advanced product development processes for BARDA-priority medical countermeasures, demonstrating their return-on-investment required for mainstream adoption.

    BARDA’s current funding mechanism for this development process is the Broad Ageny Announcement (BAA) for the Advanced Development of Medical Countermeasures for Pandemic Influenza (BAA-16-100-SOL-00002). The BAA remains open for proposals until Oct 30, 2017.

    BARDA is interested in proposals addressing translational science; specifically: the transition of novel technology from academia and Industry to pharmaceutical companies, integration of innovative CM technologies into current process development activities, or demonstration of a phase 3 commercial process proof-of-concept utilizing CM technologies.

    BARDA is part of the Department of Health and Human Services, Office of the Secretary, Assistant Secretary for Preparedness and Response.

    Antitoxins Antivirals ASPR BAA BARDA HHS Influenza Pandemic Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleSoutheast Asia Biosurveillance and Epidemiology Research
    Next Article Human Vaccines Project Launches San Diego Research Hub

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.